Omeros Showcases Zaltenibart as Promising PNH Treatment Ahead of ASH Conference

Omeros Advances Zaltenibart for PNH Treatment Ahead of ASH Conference

Omeros Corporation is set to showcase its investigational drug, zaltenibart (OMS906), at the upcoming 66th Annual Meeting of the American Society of Hematology (ASH), taking place from December 7-10, 2024, in San Diego. The presented abstracts highlight zaltenibart's promising potential as a treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare and often fatal blood disorder characterized by the destruction of red blood cells. This development is particularly significant as it comes in the context of ongoing challenges faced by patients receiving current available therapies, such as Ravulizumab, which may not provide adequate relief.

The abstracts will present interim results from a Phase 2 proof-of-concept study, indicating that zaltenibart has shown improvements in critical hematologic parameters for patients exhibiting a suboptimal response to existing treatments. The first abstract, presented by Morag Griffin, MBChB, MRCP, is scheduled for December 9 and will be cataloged as Abstract Number 4072. Meanwhile, the second abstract, which delves into the population pharmacokinetics and clinical pharmacology of zaltenibart in both healthy subjects and PNH patients, will be presented by William Pullman, BMedSc, MBBS, PhD, FRACP, as Abstract Number 4081 during the same session. This dual presentation underscores Omeros' commitment to sharing crucial insights into its investigational drug's efficacy and safety.

Looking ahead, Omeros anticipates launching Phase 3 clinical trials for zaltenibart in PNH in early 2025. The drug is designed to inhibit MASP-3, a key activator in the complement system's alternative pathway. This mechanism distinguishes zaltenibart from other alternative pathway inhibitors, as it preserves the classical pathway's lytic arm, potentially offering an enhanced defense against infections—a significant consideration for PNH patients who are often vulnerable to such complications. With the ASH congress serving as a platform for these findings, Omeros aims to solidify zaltenibart's role in advancing treatment options for patients whose needs are not fully met by current therapies.

In addition to the abstracts, Omeros plans to make the materials related to these presentations available on its website following the conference. This proactive approach reflects the company's commitment to transparency and patient education, ensuring stakeholders can access the latest information on its drug development efforts. As Omeros continues its journey through the clinical trial landscape, the upcoming ASH meeting represents a crucial milestone for zaltenibart and for the PNH patient community.